Reply Named Europe’s Leading IoT Provider by teknowlogy Group/PAC
Reply has been named Europe's leading IoT provider in IoT C&SI 2020 Survey, an industry research conducted by leading independent research and consulting company teknowlogy Group/PAC.
The survey compared 32 international consulting companies and system integrators implementing Internet of Things (IoT) projects across 24 metrics, including competitiveness, consulting skills, implementation, solution development, collaboration, customer satisfaction and business value. The ranking is divided according to global geographic regions and project scenarios like "Consulting", "Connected Vehicles", "Smart Cities" and "Digital Factory".
Reply received the "Top Ranked" award in the categories "Partner of Choice", "Industry Expertise", "Implementation Skills", "Working Culture", "Collaboration" and "Effectiveness". All these categories identify competing IoT services between all providers analysed. In other 15 categories evaluated, Reply ranked as "Leader" related to IoT projects.
The study attested Reply’s strong implementation competence for IoT Projects and industry know-how, combined with a cooperative working style and an exemplary corporate culture, demonstrating the company’s effectiveness in helping clients achieve their business objectives.
Filippo Rizzante, CTO of Reply, commented: "Reply’s positioning, given the highly competitive environment in which it operates, shows the high standard and potential of our IoT skills. Worldwide, our teams work to develop innovative IoT projects using the latest technologies in all sectors. This result underlines the high agility of the Group, which relies on a decentralized and highly specialized network of companies with extensive industry expertise and deep technology know-how".
For more information on the IoT C&SI 2020 Survey: Link
°°°
Reply
Reply [MTA, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
teknowlogy Group/PAC
teknowlogy Group is the leading independent European research and consulting firm in the fields of digital transformation, software, and IT services. It brings together the expertise of two research and advisory firms, each with a strong history and local presence in the fragmented markets of Europe: CXP and PAC (Pierre Audoin Consultants). www.teknowlogy.com and www.pac-online.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200325005044/en/
Contact information
Media:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +39 011 7711594
Aaron Miani
a.miani@reply.com
Tel. +39 02 535761
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobidiag Offers Complete Diagnostic Solution for the Detection of Novel Coronavirus Infections with Both PCR and Antibody Tests2.6.2020 06:00:00 CEST | Press release
Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address infectious diseases, antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has received CE-IVD markings for its https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmobidiag.com%2Fproducts%2Fcoronavirus-1%2F%23Novodiag-COVID-19&esheet=52228608&newsitemid=20200601005614&lan=en-US&anchor=Novodiag%26%23174%3B+COVID-19&index=1&md5=a6f8720fcb65487af8166329d2b56957 Novodiag® COVID-19 and https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmobidiag.com%2Fproducts%2Fcoronavirus-1%2F%23Amplidiag-COVID-19&esheet=52228608&newsitemid=20200601005614&lan=en-US&anchor=Amplidiag%26%23174%3B+COVID-19&index=2&md5=3dc50805e09ec072bce2a6e5aa75368a Amplidiag® COVID-19 molecular diagnostic tests for the early detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). These tests complement the Company’s al
Newmont Publishes 2019 Sustainability Report1.6.2020 15:00:00 CEST | Press release
Newmont Corporation (NYSE: NEM, TSX: NGT) (Newmont or The Company) today announced the publication of its 2019 Sustainability Report, Beyond the Mine, a transparent and comprehensive disclosure of the Company’s environmental, social and governance (ESG) performance. “Our sustainability report provides investors and other stakeholders a transparent and detailed look at look at our safety, environmental and social performance,” said Tom Palmer, President and Chief Executive Officer. “In 2019, we completed two transformative transactions whilst enhancing our ESG performance to align with our position as the world’s leading gold company.” Newmont’s 2019 sustainability highlights include: Achieving no workplace fatalities and conducting a global safety culture review, which identified several opportunities to enhance Newmont’s Fatality Risk Management program and improve the way fatality risks are managed Further strengthening management of tailings, whilst enhancing transparency through a
New Western Union research provides insight into the future of international education1.6.2020 15:00:00 CEST | Press release
The Western Union Company (NYSE: WU), a leader in cross-border, cross-currency money movement and payments, today shares a new report on “The Future of International Education,” in partnership with The Future Laboratory. The white paper highlights five new student profiles that will evolve from the shifting attitudes and behaviors of today’s youth. From Hybrid Thinkers to Greener Graduates, this new report predicts how academic institutions should adapt to meet these expectations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005162/en/ Meet the students of the future: new student profiles uncovered in “The Future of International Education” (Graphic: Business Wire) The findings come as universities and colleges worldwide are evolving to navigate COVID-19, from moving online, to delaying term dates. Institutions can use the report to ensure the new policies they introduce align with the needs and priorities of interna
FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure1.6.2020 13:00:00 CEST | Press release
The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Abiomed (NASDAQ: ABMD) manufactures Impella RP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005257/en/ Impella RP is now FDA indicated for COVID-19 related complications, including pulmonary embolism. (Photo: Business Wire) Impella RP is a temporary heart pump that provides circulatory support for patients who develop right side ventricular failure. Five years of pre- and post-market clinical studies support Impella RP’s safety and efficacy. In 2017, Impella RP received FDA approval as safe and effective for treating right ventricular failure in the setting of acute myocardial infarction and after cardiac surgery. Biventricular cardiac support can be provided when Impella RP is
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation1.6.2020 13:00:00 CEST | Press release
Vivet Therapeutics announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3 (PFIC3). PFIC3 is a rare life-threatening and chronically debilitating condition due to progressive severe liver dysfunction, accompanied by jaundice, portal hypertension, hepatosplenomegaly and failure to thrive. The symptoms of the disease usually appear first in childhood with progressive cholestasis, evolving to hepatic failure, cirrhosis and need for liver transplantation. “We are very pleased to receive these designations which further validate Vivet’s efforts to treat rare inherited metabolic disorders. The FDA and EC have both recognized the unmet need for a safe and effective treatment of PFIC3 and the potential of VTX-803 to address such need. The field of Progressive Familial Intrahepatic Cholest
Zynga Enters Into Agreement to Acquire Istanbul-based Peak, Creator of Top Charting Mobile Franchises Toon Blast and Toy Blast1.6.2020 13:00:00 CEST | Press release
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, today announced it has entered into a definitive agreement to acquire Peak, one of the most globally successful mobile gaming companies, for $1.8 billion. Peak brings a 100-person strong team and two Forever Franchises, Toon Blast and Toy Blast, that have consistently ranked in the top 10 and top 20 U.S. iPhone grossing games for over two years, respectively. These franchises add significant scale to Zynga’s live services and will be an additional driver of margin expansion over the coming years. Peak also enhances Zynga’s new game pipeline with additional projects in early development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005142/en/ Zynga Enters Into Agreement to Acquire Istanbul-based Peak, Creator of Top Charting Mobile Franchises Toon Blast and Toy Blast (Graphic: Business Wire) Founded in 2010 by Sidar Sahin, Peak has developed the